Skip to main content

Table 1 Effects of plant sterol ester capsules on plasma lipid profiles and CRP (n = 16)1

From: The lipid lowering effect of plant sterol ester capsules in hypercholesterolemic subjects

Parameters Initial Baseline2 Day 7 Day 21 Δ PSE-Placebo Day 28 Δ PSE-Placebo
Total Cholesterol (mg/dL) 256.0 ± 24.3      
Placebo phase   238.4 ± 18.8 239.3 ± 28.3   241.6 ± 27.2  
Treatment phase   239.9 ± 29.6 237.4 ± 29.2 -1.9 (-1%) 230.4 ± 22.3 -11.2 (-5%)
LDL (mg/dL) 177.1 ± 22.8      
Placebo phase   168.5 ± 22.9 169.8 ± 25.6   169.4 ± 27.0  
Treatment phase   170.8 ± 27.7 157.8 ± 22.8 A, a -12 (-7%) 163.3 ± 27.0A -6.1 (-4%)
HDL (mg/dL) 57.8 ± 19.9      
Placebo phase   50.4 ± 13.8 49.1 ± 13.6   51.2 ± 15.4  
Treatment phase   50.8 ± 15.5 53.3 ± 16.3A, a 4.2 (9%) 53.5 ± 16.3a 2.3 (4%)
Triglycerides 125.9 ± 81.4      
Placebo phase   116.6 ± 60.8 122.7 ± 89.0   126.5 ± 74.6  
Treatment phase   111.4 ± 69.8 121.7 ± 71.4 -1 (< -1%) 115.7 ± 63.6 -10.8 (-9%)
Total Cholesterol/HDL 4.89 ± 1.64      
Placebo phase   5.1 ± 1.4 5.2 ± 1.6   5.1 ± 1.6  
Treatment phase   5.1 ± 1.5 4.8 ± 1.6A, a -0.4 (-8%) 4.7 ± 1.4A, a -0.4 (-8%)
LDL/HDL 3.44 ± 1.28      
Placebo phase   3.6 ± 1.3 3.6 ± 1.2   3.7 ± 1.2  
Treatment phase   3.7 ± 1.2 3.4 ± 1.2 A, a -0.2 (-6%) 3.3 ± 1.2A, a -0.4 (-10%)
CRP (mg/dL) 0.8 ± 0.5      
Placebo phase   0.7 ± 0.4 0.7 ± 0.4   0.7 ± 0.5  
Treatment phase   0.8 ± 0.6 0.8 ± 0.5 0.07 (5%) 0.7 ± 0.3 0
  1. 1 Values are means ± SD.
  2. 2 Initial baseline measurement was done 6 week before the placebo phase. Therefore, the data was not included in any analysis, but are provided as reference information
  3. A Significantly different from placebo, p < 0.05 (paired t-test)
  4. a Significantly different within phase, p < 0.05 (1-way repeated measure ANOVA)